| Literature DB >> 33655052 |
Junjie Huang1, Paul S F Chan1, Tiffany W Y Pang1, Peter Choi1, Xiao Chen1, Veeleah Lok1, Zhi-Jie Zheng2, Martin C S Wong1,2,3.
Abstract
Background and study aims Serrated lesions are precursors of approximately one-third of colorectal cancers (CRCs). Information on their detection rate was lacking as an important reference for CRC screening. This study was a systematic review and meta-analysis to determine the overall detection rate for serrated lesions and their subtypes in average-risk populations undergoing CRC screening with colonoscopy. Patient and methods MEDLINE and Embase were searched to identify population-based studies that reported the detection rate for serrated lesions. Studies on average-risk populations using colonoscopy as a screening tool were included. Metaprop was applied to model within-study variability by binomial distribution, and Freeman-Tukey Double Arcsine Transformation was adopted to stabilise the variances. The detection rate was presented in proportions using random-effects models. Results In total, 17 studies involving 129,001 average-risk individuals were included. The overall detection rates for serrated lesions (19.0 %, 95 % CI = 15.3 %-23.0 %), sessile serrated polyps (2.5 %, 95 % CI = 1.5 %-3.8 %), and traditional serrated adenomas (0.3 %, 95 % CI = 0.1 %-0.8 %) were estimated. Subgroup analysis indicated a higher detection rate for serrated lesions among males (22.0 %) than females (14.0 %), and Caucasians (25.9 %) than Asians (14.6 %). The detection rate for sessile serrated polyps was also higher among Caucasians (2.9 %) than Asians (0.7 %). Conclusions This study determined the overall detection rate for serrated lesions and their different subtypes. The pooled detection rate estimates can be used as a reference for establishing CRC screening programs. Future studies may evaluate the independent factors associated with the presence of serrated lesions during colonoscopy to enhance their rate of detection. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).Entities:
Year: 2021 PMID: 33655052 PMCID: PMC7895666 DOI: 10.1055/a-1333-1776
Source DB: PubMed Journal: Endosc Int Open ISSN: 2196-9736
Fig. 1 PRISMA flow diagram. From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6 (7): e1000097. doi:10.1371/journal.pmed1000097
Characteristics of included studies (N = 17).
| Study | Region | State/city | Study type | Data collection | Ethnicity | Sample size | Male proportion (%) | Mean age/(age range) |
| Liang 2012 | USA | Cleveland | 1 | 1996–2006 | Caucasians | 18,003 | 56.1 | 61.4 |
| Kahi 2011 | USA | Indiana | 1 | 2000–2009 | Caucasians | 6,681 | 49 | 58.9 |
| Hetzel 2010 | USA | Boston | 1 | 2006–2008 | Caucasians | 7,192 | 44 | 58 |
| Abdeljaward 2015 | USA | Indiana | 1 | 2005–2012 | Caucasians | 1,910 | 46.2 | (≥ 50) |
| Sanaka 2014 | USA | Cleveland | 1 | 2008–2009 | Caucasians | 2,167 | 52 | (≥ 50) |
| Ross 2015 | USA | Texas | 1 | 2010–2013 | Mixture | 2,833 | 35.4 | (50–75) |
| Pyo 2017 | South Korea | Seoul | 1 | 2002–2012 | Asians | 35,126 | 50.5 | 48.5 |
| Min 2012 | South Korea | Seoul, Chungcheongnam-do | 1 | 2007–2008 | Asians | 926 | 52.1 | (> 45) |
| Kim 2014 | South Korea | Seoul | 1 | 2005–2012 | Asians | 28544 | 60.8 | (22–88) |
| Lee 2013 | South Korea | Seoul | 1 | 2011–2012 | Asians | 1,375 | 52.4 | (> 50) |
| Wijkerslooth 2013 | Netherlands | Amsterdam, Rotterdam | 1 | 2009–2010 | Caucasians | 1,354 | NA | (50–75) |
| Hazewinkel 2014 | Netherlands | Amsterdam, Rotterdam | 1 | 2009–2010 | Caucasians | 1426 | 51 | (50–75) |
| Grobbee 2017 | Netherlands | Amsterdam, Rotterdam | 1 | 2009–2010 | Caucasians | 1,256 | 51 | (50–75) |
| Leung 2012 | Hong Kong | Hong Kong | 1 | 2008–2011 | Asians | 1,282 | 48.4 | 49.1 |
| Chang 2017 | Taiwan | Taipei | 1 | 2010–2014 | Asians | 6,198 | 51.1 | (≥ 50) |
| Buda 2012 | Italy | Feltre | 1 | 2007–2008 | Caucasians | 985 | 38 | (≥ 50) |
| Ijspeert 2016 | Poland | NA | 1 | 2009–2012 | Caucasians | 12361 | NA | (50–65) |
Notes: Study type: 1 = cross-sectional, 2 = cohort
NA, not available
Quality assessment of included studies based on the Newcastle-Ottawa Scale.
| Study | Representativeness of the sample | Ascertainment of the exposure | Ascertainment of the outcome |
Ascertainment of the outcome (quality control)
|
Control for the most important factor (age or gender)
|
Control any additional factor
| Total Score |
| Hetzel 2010 | 0 | 0 | 1 | 0 | 2 | 2 | 5 |
| Kahi 2011 | 1 | 1 | 1 | 0 | 0 | 2 | 5 |
| Buda 2012 | 1 | 1 | 1 | 1 | 2 | 1 | 7 |
| Leung 2012 | 0 | 1 | 1 | 1 | 1 | 1 | 5 |
| Liang 2012 | 0 | 0 | 1 | 1 | 0 | 0 | 2 |
| Min 2012 | 1 | 1 | 1 | 1 | 2 | 1 | 7 |
| Lee 2013 | 0 | 1 | 1 | 1 | 1 | 1 | 5 |
| Wijkerslooth 2013 | 1 | 1 | 1 | 1 | 2 | 0 | 6 |
| Hazewinkel 2014 | 1 | 1 | 1 | 1 | 2 | 1 | 7 |
| Kim 2014 | 0 | 1 | 1 | 1 | 2 | 1 | 6 |
| Sanaka 2014 | 0 | 1 | 1 | 1 | 1 | 1 | 5 |
| Abdeljaward 2015 | 1 | 1 | 1 | 0 | 0 | 1 | 4 |
| Ross 2015 | 1 | 1 | 1 | 1 | 1 | 1 | 6 |
| Ijspeert 2016 | 1 | 0 | 1 | 1 | 2 | 1 | 6 |
| Chang 2017 | 0 | 1 | 1 | 1 | 0 | 0 | 3 |
| Grobbee 2017 | 1 | 0 | 1 | 1 | 1 | 1 | 5 |
| Pyo 2017 | 0 | 1 | 1 | 1 | 2 | 0 | 5 |
One point for studies reported the quality of the endoscopy.
One point for age, one point for gender, total can get two points in this section.
Studies can get one point if they report either one category and two points for two or more categories: race/region/site/screening year.
Fig. 2 Detection rates for serrated lesions, sessile serrated polyps, and traditional serrated adenomas.
Results of multivariate regression.
| Serrated lesions | SSP | TSA | ||||
| Coefficient | P value | Coefficient | P value | Coefficient | P value | |
| Overall | 0.159 | 0.383 | 0.021 | 0.693 | 0.009 | 0.740 |
| Setting | ||||||
National screening program/large cohort study | – | – | – | |||
Multiple centers | Reference | Reference | – | |||
Single hospital/site | –0.204 | 0.848 | –0.037 | 0.294 | – | |
|
Study period
| ||||||
2006–2010 | Reference | Reference | – | |||
2011–2014 | 0.012 | 0.870 | 0.020 | 0.444 | – | |
| Smoking proportion | ||||||
< 50 % | – | –0.015 | 0.689 | –0.009 | 0.762 | |
≥ 50 % | Reference | Reference | Reference | |||
| NM | 0.059 | 0.721 | 0.007 | 0.879 | –0.002 | 0.929 |
| Definition | ||||||
WHO | – | –0.014 | 0.744 | – | ||
NM | – | Reference | – | |||
| Study quality (NOS score) | ||||||
≤ 5 | 0.159 | 0.383 | 0.019 | 0.495 | –0.003 | 0.900 |
> 5 | Reference | Reference | Reference | |||
SSP, sessile serrated polyps; TSA, traditional serrated polyps; coef, coefficient; NM, not mentioned.
Study period was categorized by the upper limit of the data collection period range.
Characteristics of included studies (N = 17).
| Study | Setting | Detection method | Smoker proportion | Routine vs opportunistic | Definition_SL | Definition_location | SL (%) | HP (%) | SSP (%) | TSA (%) |
| Liang 2012 | 3 | 1 | NA | 1 | WHO | – | 20.6 | – | – | – |
| Kahi 2011 | 2 | 1 | NA | 1 | WHO | a | 13.0 | – | – | – |
| Hetzel 2010 | 3 | 1 | NA | 1 | – | a | – | 11.7 | 0.6 | – |
| Abdeljaward 2015 | 2 | 1 | NA | 1 | WHO | a | 20.4 | – | 8.1 | 0.4 |
| Sanaka 2014 | 3 | 1 | NA | 1 | – | a | – | – | 1.8 | – |
| Ross 2015 | 2 | 1 | NA | 1 | – | – | – | – | 8.2 | – |
| Pyo 2017 | 3 | 1 | 28.4 | 1 | WHO | b | – | – | 0.5 | 0.6 |
| Min 2012 | 2 | 1 | NA | 1 | WHO | a | 11.9 | – | – | – |
| Kim 2014 | 3 | 1 |
59.7
| 1 | WHO | a | 15.1 | 14.7 | 0.5 | 0.1 |
| Lee 2013 | 3 | 1 | NA | 1 | WHO | a | 11.3 | – | – | – |
| Wijkerslooth 2013 | 2 | 1 | NA | 1 | WHO | a | 12.3 | – | – | – |
| Hazewinkel 2014 | 2 | 1 | NA | 1 | WHO | a | 27.2 | 23.8 | 4.8 | 0.1 |
| Grobbee 2017 | 2 | 1 | NA | 1 | – | – | – | 12.7 | 3.0 | – |
| Leung 2012 | 3 | 1 | NA | 1 | WHO | b | 21.4 | – | – | – |
| Chang 2017 | 3 | 1 | 20.1 | 1 | WHO | – | – | 1.9 | 1.4 | – |
| Buda 2012 | 2 | 1 | NA | 1 | WHO | – | – | 4.6 | 2.3 | 0.5 |
| Ijspeert 2016 | 2 | 1 | NA | 1 | WHO | a | 26.6 | – | 2.2 | 0.8 |
Setting: 1 = national screening program, 2 = multiple centers, 3 = single
hospital/site; Detection method: 1 = colonoscopy, 2 = Sigmoidoscopy; Routine vs. opportunistic: 1 = rountine,
2 = opportunistic; Screening vs. surveillance: 1 = Screening, 2 = Screening and surveillance.
NA, not available
WHO: Serrated lesions (SLs) were classified according to WHO criteria as hyperplastic polyps (HP), sessile serrated polyp (SSP) without cytologic dysplasia, SSP with cytologic dysplasia (SSP-CD), traditional serrated adenoma (TSA) with and without conventional dysplasia, and serrated polyps unclassified; a: The proximal colon was defined as proximal to the splenic flexure; b: The proximal colon was defined as proximal to transverse colon.
Adenoma group
Serrated lesions group